Showing results (151-160 of 167) with videos related to
Sort By:
Pageof 17
BMC Cancer|June 15, 2019
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)Roche Kapoor, Matthew P Deek, Riley McIntyre, et al.JAMA Oncology|March 28, 2020
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical TrialRyan Phillips, William Yue Shi, Matthew Deek, et al.BMC Cancer|June 4, 2020
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)Hamza Hasan, Matthew P Deek, Ryan Phillips, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2022
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA TrialPhuoc T Tran, Kathryn Lowe, Hua-Ling Tsai, et al.Neuro-Oncology|November 8, 2023
Inhibition of ATR opposes glioblastoma invasion through disruption of cytoskeletal networks and integrin internalization via macropinocytosisSarah J Derby, Louise Dutton, Karen E Strathdee, et al.Cell Reports|March 7, 2025
ARHGAP12 and ARHGAP29 exert distinct regulatory effects on switching between two cell morphological states through GSK-3 activityVinton W T Cheng, Philippa Vaughn-Beaucaire, Gary C Shaw, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2025
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized TrialJarey H Wang, Alexander D Sherry, Soha Bazyar, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor modelsCherrie K Donawho, Yan Luo, Yanping Luo, et al.International Journal of Radiation Oncology, Biology, Physics|July 7, 2018
Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium StudyKiri A Sandler, Ryan R Cook, Jay P Ciezki, et al.JAMA Oncology|October 22, 2020
Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the ProstateRobert T Dess, Krithika Suresh, Michael J Zelefsky, et al.Pageof 17